Theravance Biopharma (TBPH) Stock Price, News & Analysis

Company Overview

Theravance Biopharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on respiratory disorders and other conditions where there is a significant unmet medical need. The company’s research and development activities have historically centered on therapies designed to improve lung function and address chronic respiratory disease.

Its principal marketed product is Yupelri (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Yupelri is commercialized in collaboration with Viatris. Theravance Biopharma also receives royalty revenues connected with Trelegy Ellipta, an inhaled treatment for COPD and asthma developed and commercialized by GSK under a licensing arrangement.

Theravance Biopharma was established following the 2014 separation of the biopharmaceutical operations of Theravance, Inc. from the company’s royalty-focused business. The company is headquartered in Dublin, Ireland, and serves international markets primarily through commercial and development partnerships. Rick E. Winningham has served as the company’s chief executive officer and chairman.

Key Stats

• Today's Range: $17.03 to $17.03
• 50-Day Range: $16.95 to $17.08
• 52-Week Range: $13.08 to $21.03
• Volume: N/A
• Average Volume: 680,323 shs
• Market Capitalization: $884.18 million
• P/E Ratio: 16.86
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Hold

Theravance Biopharma Stock Analysis - MarketRank™

Theravance Biopharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 727th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Hold

Consensus Rating

Theravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and no sell ratings.

Upside Potential

Theravance Biopharma has a consensus price target of $19.00, representing about 11.6% upside from its current price of $17.03.

Amount of Analyst Coverage

Theravance Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -48.08%

Earnings Growth

Earnings for Theravance Biopharma are expected to decrease by -48.08% in the coming year, from $1.56 to $0.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.42.

Price to Book Value per Share Ratio

Theravance Biopharma has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.52% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Theravance Biopharma has recently increased by 4.21%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theravance Biopharma does not currently pay a dividend.

Dividend Growth

Theravance Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $226,737.00 in company stock.

Percentage Held by Insiders

7.65% of the stock of Theravance Biopharma is held by insiders.

Percentage Held by Institutions

99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/30/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TBPH
• Previous Symbol: NASDAQ:TBPHV
• CIK: 1583107
• Web: www.theravance.com
• Phone: (650) 808-6000
• Fax: N/A
• Employees: 110
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Theravance Biopharma: $19.00
• High Price Target: $27.00
• Low Price Target: $15.00
• Potential Upside/Downside: +11.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.01
• Trailing P/E Ratio: 16.86
• Forward P/E Ratio: 10.92
• P/E Growth: N/A
• Net Income: $105.89 million
• Net Margins: 51.58%
• Pretax Margin: 56.48%
• Return on Equity: -0.77%
• Return on Assets: -0.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.54
• Quick Ratio: 13.54

Sales & Book Value

• Annual Sales: $104.31 million
• Price / Sales: 8.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.86 per share
• Price / Book: 2.91

Miscellaneous

• Outstanding Shares: 51,919,000
• Free Float: 47,947,000
• Market Cap: $884.18 million
• Optionable: Optionable
• Beta: 0.25